EBS:NYE-Emergent Biosolutions Inc (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 9.35

Change

0.00 (0.00)%

Market Cap

N/A

Volume

1.12M

Analyst Target

USD 112.29
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-20 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
ZTS Zoetis Inc

N/A

USD 87.57B
HLN Haleon plc

N/A

USD 45.67B
TAK Takeda Pharmaceutical Co Ltd A..

N/A

USD 45.20B
RDY Dr. Reddy’s Laboratories Ltd..

N/A

USD 13.38B
CTLT Catalent Inc

N/A

USD 10.94B
ELAN Elanco Animal Health

N/A

USD 6.34B
BHC Bausch Health Companies Inc

N/A

USD 3.00B
AMRX Amneal Pharmaceuticals, Inc. C..

N/A

USD 2.66B
CPHI China Pharma Holdings Inc

N/A

USD 4.27M
YCBD cbdMD Inc

N/A

USD 1.92M

ETFs Containing EBS

XB4A:XETRA Xtrackers ATX UCITS ETF 1.. 19.81 % 0.00 %

N/A

USD 0.05B
EXXX:XETRA iShares ATX UCITS ETF (DE.. 19.51 % 0.00 %

N/A

USD 0.09B
EBNK:CA Evolve European Banks Enh.. 5.06 % 0.00 %

N/A

CAD 3.37M
IS3H:XETRA iShares MSCI EMU Mid Cap .. 1.83 % 0.00 %

N/A

USD 0.13B
EMUM:SW iShares MSCI EMU Mid Cap .. 1.83 % 0.00 %

N/A

USD 0.14B
LDEG:LSE L&G Quality Equity Divide.. 1.30 % 0.00 %

N/A

N/A
PRFZ Invesco FTSE RAFI US 1500.. 0.00 % 0.39 %

N/A

USD 2.55B
IS3H:F iShares IV Public Limited.. 0.00 % 0.00 %

N/A

N/A
EL43:XETRA Deka MSCI Europe MC UCITS.. 0.00 % 0.00 %

N/A

USD 0.02B
IVES Amplify ETF Trust 0.00 % 0.00 %

N/A

USD 0.02B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 289.58% 87% B+ 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 289.58% 87% B+ 95% A
Trailing 12 Months  
Capital Gain 323.08% 87% B+ 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 323.08% 87% B+ 95% A
Trailing 5 Years  
Capital Gain -82.77% 14% F 3% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -82.77% 14% F 8% B-
Average Annual (5 Year Horizon)  
Capital Gain -32.82% 7% C- 1% F
Dividend Return -32.82% 7% C- 1% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 61.75% 27% F 14% F
Risk Adjusted Return -53.16% 13% F 5% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector